#USA #Irvine #Endometriosis #EndoCyclic #ENDO-205

EndoCyclic Therapeutics and the Future of Endometriosis Treatment

On March 23, 2026, EndoCyclic Therapeutics, a biopharmaceutical innovator based in Irvine, California, announced a significant leap forward in women's health. The U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application for ENDO-205, setting the stage for clinical trials of a first-of-its-kind non-hormonal peptide therapeutic aimed at treating endometriosis.

The Road to Clinical Trials

END-205 is not just another treatment that merely alleviates the symptoms associated with endometriosis—this therapy aims to tackle the disease's root causes directly. Unlike conventional methods that focus primarily on hormonal manipulation to suppress symptoms, ENDO-205's innovative approach targets endometriosis lesions, offering patients hope of not only relief but also a more effective long-term solution. The company is set to embark on Phase 1 clinical studies involving healthy pre-menopausal women of reproductive age, marking a pivotal chapter in endometriosis research and treatment.

Dr. Tanya Petrossian, the founder and CEO of EndoCyclic Therapeutics, expressed enthusiasm about this milestone, stating, "FDA IND clearance validates the strong scientific foundation behind ENDO-205 and the work of our deeply experienced team in research and development, regulatory affairs, and product development." Her enthusiasm underlines not just the achievement but also the profound impact this treatment could have on over 190 million women worldwide suffering from this often-overlooked condition.

Understanding Endometriosis

Endometriosis is a complex and chronic disease that affects around 10 percent of women during their reproductive years. The condition is characterized by the growth of endometrial-like tissue outside the uterus, leading to debilitating pain, infertility, and a host of related health issues. The inability of current hormonal therapies to eliminate the lesions associated with the disease underscores the urgent need for innovative treatments like ENDO-205.

Importantly, past treatments have often fallen short, leading to ongoing pain, recurrence, and the need for surgical interventions. With ENDO-205, patients may find an opportunity for a therapeutic approach that aims for more than just symptom control, tackling the underlying biology that triggers the condition.

A Decade of Research

The development of ENDO-205 is rooted in a decade's worth of meticulous research focused on understanding the pathology of endometriosis. Utilizing EndoCyclic's proprietary peptide platform, researchers designed this therapy to selectively target diseased tissue without compromising the patient's hormonal balance or invoking systemic side effects. Preliminary studies have shown promising results, with ENDO-205 effectively eliminating endometriosis lesions and associated inflammation without revealing safety concerns—a crucial factor that supports its transition into clinical trials.

The project has garnered substantial backing from various NIH grants, illustrating the scientific community's recognition of its potential. In 2025, ENDO-205 earned an NIH Commercialization Readiness Pilot Grant with a perfect impact score of 10, underscoring its innovative nature and commercial viability. This achievement positions EndoCyclic Therapeutics among the leaders in the quest to pioneer new treatments in women's health.

A Vision for Women's Health

In addition to ENDO-205, the company is committed to expanding its reach in women's health through initiatives like FemLUNA, an investigational imaging tool designed for non-invasive detection of endometriosis. This effort reflects EndoCyclic's broader strategy to provide better diagnostic and therapeutic options for women facing similar health challenges.

As EndoCyclic Therapeutics takes this monumental step forward, the eyes of the medical community will be keenly observing. Successful trials and subsequent approval of ENDO-205 could fundamentally reshape how endometriosis is treated, paving the way for targeted, effective interventions that prioritize women's health. With a commitment grounded in scientific rigor and patient-centricity, EndoCyclic is poised to become a leading innovator in biopharmaceutical development in the field of women's health.